OBJECTIVE: Treatment delays have been associated with adverse outcomes in patients with bladder cancer treated with radical cystectomy (RC). We sought to evaluate the impact of treatment delay on disease recurrence and survival in patients with bladder cancer treated with partial cystectomy (PC) in Quebec. METHODS: We reviewed and obtained billing records for all patients who underwent PC and/or RC for bladder cancer in Quebec between 1983 and 2005. Analysis included age, sex, year of surgery, surgeon's age, hospital type, preoperative and postoperative visits with accompanying diagnoses and dates of death. RESULTS: A total of 714 patients underwent PC. The median patient age was 70 years. Two-hundred nineteen (30.7%) patients experienced recurrence; of these, 52 (23.7%) required salvage RC. Five-year overall and recurrence-free survival for patients who underwent PC were 49.8% and 40.3%, respectively. Patients delayed more than 12 weeks from transurethral resection of bladder tumours (TURBT) to PC were at significantly increased risk of requiring salvage RC compared with those delayed 12 weeks or less (hazard ratio [HR] 3.0, p < 0.001). Patients who underwent salvage RC had worse survival than patients who had upfront RC (HR 1.5, p = 0.006). Variables including age, sex, presence of hematuria, intravesical therapy, surgeon age, hospital PC volume, surgeon PC volume, type of hospital (academic v. nonacademic) or year of surgery were not significantly associated with PC treatment delay. CONCLUSION: Treatment delay in patients with bladder cancer managed with PC was associated with increased risk of salvage RC. Patients with bladder cancer who underwent salvage RC had worse outcomes than those who had upfront cystectomy.
OBJECTIVE: Treatment delays have been associated with adverse outcomes in patients with bladder cancer treated with radical cystectomy (RC). We sought to evaluate the impact of treatment delay on disease recurrence and survival in patients with bladder cancer treated with partial cystectomy (PC) in Quebec. METHODS: We reviewed and obtained billing records for all patients who underwent PC and/or RC for bladder cancer in Quebec between 1983 and 2005. Analysis included age, sex, year of surgery, surgeon's age, hospital type, preoperative and postoperative visits with accompanying diagnoses and dates of death. RESULTS: A total of 714 patients underwent PC. The median patient age was 70 years. Two-hundred nineteen (30.7%) patients experienced recurrence; of these, 52 (23.7%) required salvage RC. Five-year overall and recurrence-free survival for patients who underwent PC were 49.8% and 40.3%, respectively. Patients delayed more than 12 weeks from transurethral resection of bladder tumours (TURBT) to PC were at significantly increased risk of requiring salvage RC compared with those delayed 12 weeks or less (hazard ratio [HR] 3.0, p < 0.001). Patients who underwent salvage RC had worse survival than patients who had upfront RC (HR 1.5, p = 0.006). Variables including age, sex, presence of hematuria, intravesical therapy, surgeon age, hospital PC volume, surgeon PC volume, type of hospital (academic v. nonacademic) or year of surgery were not significantly associated with PC treatment delay. CONCLUSION: Treatment delay in patients with bladder cancer managed with PC was associated with increased risk of salvage RC. Patients with bladder cancer who underwent salvage RC had worse outcomes than those who had upfront cystectomy.
Authors: K Inoue; J W Slaton; P Perrotte; D W Davis; C J Bruns; D J Hicklin; D J McConkey; P Sweeney; R Radinsky; C P Dinney Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: Ricardo F Sánchez-Ortiz; William C Huang; Rosemarie Mick; Keith N Van Arsdalen; Alan J Wein; S Bruce Malkowicz Journal: J Urol Date: 2003-01 Impact factor: 7.450
Authors: Bjoern G Volkmer; Rainer Kuefer; Georg Bartsch; Michael Straub; Robert de Petriconi; Juergen E Gschwend; Richard E Hautmann Journal: Cancer Date: 2005-12-01 Impact factor: 6.860
Authors: Wassim Kassouf; David Swanson; Ashish M Kamat; Dan Leibovici; Arlene Siefker-Radtke; Mark F Munsell; H Barton Grossman; Colin P N Dinney Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Jeffrey M Holzbeierlein; Ernesto Lopez-Corona; Bernard H Bochner; Harry W Herr; S Machele Donat; Paul Russo; Guido Dalbagni; Pramod C Sogani Journal: J Urol Date: 2004-09 Impact factor: 7.450
Authors: Shivanshu Awasthi; Travis Gerke; Jong Y Park; Francis A Asamoah; Vonetta L Williams; Angelina K Fink; Rajesh Balkrishnan; David I Lee; S Bruce Malkowicz; Priti Lal; Jasreman Dhillon; Julio M Pow-Sang; Timothy R Rebbeck; Kosj Yamoah Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-11-09 Impact factor: 4.254
Authors: Paweł Grzegółkowski; Krystian Kaczmarek; Artur Lemiński; Michał Soczawa; Adam Gołąb; Marcin Słojewski Journal: Cent European J Urol Date: 2016-12-30